You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

CLINICAL TRIALS PROFILE FOR SOMATULINE DEPOT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Somatuline Depot

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149188 ↗ Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed Ipsen Phase 4 2004-02-01 The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be assessed.
NCT00216398 ↗ Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed Ipsen Phase 4 2004-06-01 The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
NCT00288522 ↗ Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated Ipsen Phase 2 2006-01-01 The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.
NCT00444873 ↗ Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed Ipsen Phase 3 2005-01-01 A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.
NCT00447499 ↗ Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed Ipsen Phase 3 2007-04-01 The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
NCT00517491 ↗ Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) Withdrawn Ipsen Phase 2 2008-05-01 The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)
NCT00681187 ↗ Somatuline Autogel Preference and Health Economy Study Completed Ipsen Phase 4 2008-06-01 The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somatuline Depot

Condition Name

Condition Name for Somatuline Depot
Intervention Trials
Acromegaly 9
NeuroEndocrine Tumours 2
Neuroendocrine Tumors 2
Neuroendocrine Tumour With Carcinoid Symptoms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Somatuline Depot
Intervention Trials
Acromegaly 9
Neuroendocrine Tumors 8
Carcinoid Tumor 7
Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Somatuline Depot

Trials by Country

Trials by Country for Somatuline Depot
Location Trials
United States 44
Belgium 10
Netherlands 8
United Kingdom 6
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Somatuline Depot
Location Trials
California 6
Oregon 3
New York 3
Maryland 3
Colorado 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Somatuline Depot

Clinical Trial Phase

Clinical Trial Phase for Somatuline Depot
Clinical Trial Phase Trials
Phase 4 6
Phase 3 8
Phase 2 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Somatuline Depot
Clinical Trial Phase Trials
Completed 13
Terminated 4
Unknown status 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Somatuline Depot

Sponsor Name

Sponsor Name for Somatuline Depot
Sponsor Trials
Ipsen 19
Radboud University 2
Erasmus Medical Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Somatuline Depot
Sponsor Trials
Other 28
Industry 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.